GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » LT-Debt-to-Total-Asset

D&D Pharmatech (XKRX:347850) LT-Debt-to-Total-Asset : 0.06 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. D&D Pharmatech's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.06.

D&D Pharmatech's long-term debt to total assets ratio increased from Jun. 2023 (0.00) to Sep. 2024 (0.06). It may suggest that D&D Pharmatech is progressively becoming more dependent on debt to grow their business.

D&D Pharmatech LT-Debt-to-Total-Asset Historical Data

The historical data trend for D&D Pharmatech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech LT-Debt-to-Total-Asset Chart

D&D Pharmatech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.01 0.02 0.03 0.07 0.07

D&D Pharmatech Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial - 0.07 0.07 0.05 0.06

D&D Pharmatech LT-Debt-to-Total-Asset Calculation

D&D Pharmatech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=5120.622/79203.645
=0.06

D&D Pharmatech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=6092.239/101523.763
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D&D Pharmatech  (XKRX:347850) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

D&D Pharmatech LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR
Website
http://www.ddpharmatech.com
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines